Transfusion-associated graft versus host disease skin punch biopsy

Transfusion-associated graft versus host disease Microchapters
Home
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Transfusion-associated graft versus host disease from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Biomarker Panel
Chest X Ray
HLA analysis
Skin Punch Biopsy
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Transfusion-associated graft versus host disease skin punch biopsy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Transfusion-associated graft versus host disease skin punch biopsy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Transfusion-associated graft versus host disease skin punch biopsy
CDC on Transfusion-associated graft versus host disease skin punch biopsy
Transfusion-associated graft versus host disease skin punch biopsy in the news
Blogs on Transfusion-associated graft versus host disease skin punch biopsy
Directions to Hospitals Treating Transfusion-associated graft versus host disease
Risk calculators and risk factors for Transfusion-associated graft versus host disease skin punch biopsy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Skin Punch Biopsy

TA-GvHD can be suspected from a biopsy of the affected skin, and established by HLA analysis of the circulating lymphocytes. This testing can identify circulating lymphocytes with a different HLA type than the tissue cells of the host.